target price 22 cents, page-5

The stock is a myth kept pumping by rumours. The latest rumour is that they will get a big international partner to move in.

Oddly when these failed underdeveloped ideas find a partner if they have anything at all to offer they are usually bundled up as junk and are rescued at deadly diluting cost.

I'm amazed that this stock holds up and maybe the tax loss selling will take it down where it should be on disclosed form.

It's up there with the best of the ramped overvalued Aussie idea of what a biotech does.